IP Library Granted Patent US 12,180,487
Granted Patent B2
US 12,180,487 · App. 17/428,585 · Granted Dec 31, 2024

Minicircle producing bacteria engineered to differentially methylate nucleic acid molecules therein

Inventors: Christopher Johnston (Seattle, WA); Sean Cotton (Cambridge, MA)
Assignee: Fred Hutchinson Cancer Center
C12N15/70C12N1/205C12N9/1007C12N15/74C12R2001/19
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,180,487
App. No.
17/428,585
Granted
Dec 31, 2024
Kind
B2
Abstract

Embodiments include engineered minicircle-producing bacterium with differential methylation capability, as well as kits and compositions comprising the bacterium. Further described are methods of using of the bacterium for producing differentially methylated minicircle DNA, and for improving transformation efficiency of exogenous DNA in intractable bacteria.

Claims (20)

1. An engineered, minicircle producing bacterium comprising:

a parental plasmid comprising a minicircle nucleic acid sequence comprising an exogenous nucleic acid sequence and a plurality of restriction sites outside of the minicircle nucleic acid sequence,

wherein at least one endogenous methyltransferase comprising at least one of a Dam methyltransferase, a Dem methyltransferase, a HsdM methyltransferase, or a combination thereof, is absent or non-functional in the engineered bacterium, such that the engineered bacterium has reduced DNA-methylation capability and the exogenous nucleic acid sequence lacks methylation at a plurality of methylation cites that would be methylated in a reference bacterium of the same species as the engineered bacterium.

2. The engineered bacterium of claim 1 , wherein the at least one endogenous methyltransferase is non-functional in the engineered bacterium, and the engineered bacterium comprises a modification in a gene encoding a respective endogenous methyltransferase of the at least one endogenous methyltransferase.

3. The engineered bacterium of claim 1 , wherein the at least one endogenous methyltransferase methylates a cytosine residue of a sequence CCWGG, wherein the W is A or T, the at least one endogenous methyltransferase methylates an adenosine residue of a sequence GATC, a sequence AACN 6 GTGC, or both, or the at least one endogenous methyltransferase methylates a cytosine residue and an adenosine residue.

4. The engineered bacterium claim 1 , wherein the engineered bacterium is Escherichia coli.

5. The engineered bacterium of claim 1 , further comprising at least one of an inducible ϕC31 integrase or an inducible I-SceI homing endonuclease.

6. A kit comprising an engineered bacterium of claim 1 .

7. A method, comprising:

producing a minicircle comprising the exogenous DNA sequence comprised in the parental plasmid in a first bacterium that is an engineered bacterium of claim 1 ; and

transforming the minicircle into a second bacterium, the minicircle lacking methylation at a plurality of methylation sites that would be methylated in a reference bacterium of the same species as the engineered bacterium and, thereby, resisting degradation when transformed into the second bacterium.

8. A method, comprising:

transforming a parental plasmid into an engineered bacterium,

wherein the parental plasmid comprises a minicircle nucleic acid sequence comprising an exogenous nucleic acid sequence and a plurality of restriction sites outside of the minicircle nucleic acid sequence, and

wherein at least one endogenous methyltransferase comprising at least one of a Dam methyltransferase, a Dem methyltransferase, a HsdM methyltransferase, or a combination thereof, is absent or non-functional in the engineered bacterium, such that the engineered bacterium has reduced DNA-methylation capability and the exogenous nucleic acid sequence lacks methylation at a plurality of methylation cites that would be methylated in a reference bacterium of the same species as the engineered bacterium; and

producing a minicircle comprising the minicircle nucleic acid sequence, wherein the minicircle lacks methylation at a plurality of methylation sites that would be methylated in a reference bacterium of the same species as the engineered bacterium.

9. The method of claim 8 , wherein at least one endogenous methyltransferase is non-functional in the engineered bacterium, and the engineered bacterium comprises a modification in a gene encoding a respective endogenous methyltransferase of the at least one endogenous methyltransferase.

10. The method of claim 8 , wherein the at least one endogenous methyltransferase methylates a cytosine residue of a sequence CCWGG, wherein the W is A or T, the at least one endogenous methyltransferase methylates an adenosine residue of a sequence GATC, a sequence AACN6GTGC, or both, or the at least one endogenous methyltransferase methylates a cytosine residue and an adenosine residue.

11. The method of claim 7 , wherein at least one endogenous methyltransferase is non-functional in the engineered bacterium, and the engineered bacterium comprises a modification in a gene encoding a respective endogenous methyltransferase of the at least one endogenous methyltransferase.

12. The method of claim 7 , wherein the at least one endogenous methyltransferase methylates a cytosine residue of a sequence CCWGG, wherein the W is A or T, the at least one endogenous methyltransferase methylates an adenosine residue of a sequence GATC, a sequence AACN6GTGC, or both, or the at least one endogenous methyltransferase methylates a cytosine residue and an adenosine residue.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Oct 7, 2024
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 069119/0019 →
CONFIRMATORY LICENSE Recorded Dec 6, 2023
From: FRED HUTCHINSON CANCER RESEARCH CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065791/0442 →
Continuity (2)
Provisional Application 62802016 · Feb 6, 2019
Related Publication 20220098599A1 · Mar 31, 2022